Clinical Trials- Multiple Myeloma

 TITLE  PHASE  CONTACT  LOCATION
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase  2/3 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients Previously Treated Multiple Myeloma (Lilly H9S-MC-JDCG)  II/III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha
SUSPENDED 8/2013 "Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic
High-Risk Smoldering Multiple Myeloma
**Lenalidomide training required for each enrolling study physician.  (E3A06)" 
 III

Deborah Meyer, RN, BGS dmeyerk@unmc.edu 

or Penny Hardiman (402) 559-6941

--------------------------------

Marcia Grafe                          402-483-2827     mgrafe@lmep.com

----------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203  

 

Nebraska Medical Center, Omaha NE;

Nebraska Cancer Research Center, Lincoln, NE/  Lincoln Medical Education Partnership Lincoln, NE;

Missouri Valley Cancer Consortium, Omaha NE

 " A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in
Previously Treated Multiple Myeloma Patients with Impaired Renal Function  (PrE1003)" 
 I/II

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203  

----------------------------

Marcia Grafe                         402-483-2827   mgrafe@lmep.com

Missouri Valley Cancer Consortium, Omaha, NE;  

Nebraska Cancer Research Center, Lincoln, NE/  Lincoln Medical Education Partnership Lincoln, NE

A Phase III, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma (NCT01335399)  III

Deborah Meyer, RN, BGS  dmeyerk@unmc.edu

(402) 559-6941 or Penny Hardiman

 Nebraska Medical Center, Omaha, NE
Carfilzomib Multiple Myeloma Expanded Access Protocol (C-MAP) for Patients with Relapsed and Refractory Disease (Protocol 2011-002)  

Deborah Meyer, RN, BGS  dmeyerk@unmc.edu

(402) 559-6941 or Penny Hardiman

 Nebraska Medical Center, Omaha, NE
 

Phase lll Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma  (NCT01109004)

 III

Deborah Meyer, RN, BGS  dmeyerk@unmc.edu

(402) 559-6941 or Penny Hardiman

 Nebraska Medical Center, Omaha, NE

 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia  (E2905)

 **Lenalidomide training required for each enrolling study physician.

 III  

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203
  Missouri Valley Cancer Consortium, Omaha, NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software